# Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

> **NCT01090011** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 171 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Cetuximab
- **DRUG:** BIBW 2992
- **DRUG:** BIBW 2992

## Key facts

- **NCT ID:** NCT01090011
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2013-01
- **Final completion:** 2014-08
- **Target enrollment:** 171 (ACTUAL)
- **Last updated:** 2015-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01090011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01090011, "Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01090011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*